The burden of Duchenne muscular dystrophy: An international, cross-sectional study

Neurology

Volumn 83, Issue 6, 2014, Pages 529-536

  Landfeldt, Erik ^a,b   Lindgren, Peter ^b   Bell, Christopher F ^c   Schmitt, Claude ^d   Guglieri, Michela ^e   Straub, Volker ^e   Lochmüller, Hanns ^e   Bushby, Katharine ^e  

^a OptumInsight   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; CHILD; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; INTERNATIONALITY; ITALY; MALE; MUSCULAR DYSTROPHY, DUCHENNE; REGISTRIES; UNITED STATES;

EID: 84905828966     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000669     Document Type: Article

References (27)

1. Aymé S, Rodwell C. 2013 Report on the State of the Art of Rare Disease Activities in Europe. The European Union Committee of Experts on Rare Diseases [updated July 2013]. Available at: http://www.eucerd.eu/upload/file/ Reports/2013ReportStateofArtRDActivities.pdf. Accessed August 2013.
2. National Institutes of Health. FAQ about rare diseases. Available at: http://www.ncats.nih.gov/about/faq/rare/ rare-faq.html. Accessed May 2013.
3. Kirby T. Australia makes up for lost time on rare diseases. Lancet 2012;379:1689-1690.
4. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
5. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy: part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
6. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy: part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
7. Bladen CL, Rafferty K, Straub V, et al. The TREATNMD Duchenne muscular dystrophy registries: conception, design and utilisation by industry and academia. Hum Mutat 2013;34:1449-1457.
8. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the Health Utilities Index Mark 3 system. Med Care 2002;40:113-128.
9. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
10. British National Formulary (BNF). British Medical Association and the Royal Pharmaceutical Society. Available at: http://www.bnf.org. Accessed October 2012.
11. Department of Health. National schedule of reference costs 2010-11 for NHS trusts. Available at: http://www.dh.gov. uk/prod-consum-dh/groups/dh- digitalassets/documents/ digitalasset/dh-131145.xls. Accessed November 2012.
12. Personal Social Services Research Unit (PSSRU). Unit costs of health &social care 2011. Available at: http://www.pssru.ac.uk/archive/pdf/uc/ uc2011/uc2011.pdf. Accessed October 2012.
13. Die Kassenärztliche Bundesvereinigung (KBV). Einheitlicher Bewertungsmaßstab (EBM). Stand: 4. Quartal 2012. Available at: http://www.kbv.de. Accessed November 2012.
14. Rote Liste Service GmbH. Rote Liste 2012: Arzneimittelinformationen fur Deutschland. Frankfurt am Main: Rote Liste Service GmbH; 2012.
15. Mag Mutual Healthcare Solutions, Inc. Physicians' Fee &Coding Guide. Atlanta: Mag Mutual Healthcare Solutions; 2012.
16. OptumInsight, Inc. DrugReimbursement.com. Available at: http://www.drugreimbursement.com. Accessed October 2012.
17. Prontuario Farmaceutico Italiano. Available at: http:// www.prontuariofarmaceutico.it. Accessed March 2013.
18. Regione Emilia Romagna. Nomenclatore tariffario regionale (in vigore dall'1 marzo 2013). Available at: http://www.saluter.it/ documentazione/ nomenclatore-tariffario-rer/nomenclatore- tariffario-rer-marzo2013.pdf/view. Accessed April 2013.
19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-365.
20. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641.
21. The Organisation for Economic Co-operation and Development (OECD). Work-life balance. Available at: http://www.oecdbetterlifeindex.org/topics/work- life-balance. Accessed August 2012.
22. Johannesson M, Borgquist L, Jonsson B, Rastam L. The costs of treating hypertension: an analysis of different cutoff points. Health Policy 1991;18:141-150.
23. United States Department of Transportation. The value of travel time savings: departmental guidance for conducting economic evaluations, revision 2 (2011). Available at: http://www.dot.gov/sites/dot.dev/files/docs/vot-guidance- 092811c.pdf. Accessed March 2013.
24. Organisation for Economic Co-operation and Development. OECD.Stat Extracts. Available at: http://stats. oecd.org. Accessed August 2013.
25. Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. J Child Neurol 2008;23:883-888.
26. Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve 2014;49:431-438.
27. Statistics Canada. National population health survey overview. Available at: http://www5.statcan.gc.ca/bsolc/olc-cel/olc-cel? lang5eng&catno582-567- X. Accessed October 2012.